This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene's New Multiple Myeloma Drug Is Kicking Amgen's Ass

CELG Chart CELG data by YCharts

SUMMIT, NJ ( TheStreet) -- Celgene (CELG - Get Report) issued another "beat and raise" earnings report for the third quarter earnings -- pretty much standard operating procedure these days -- but take a look at the company's new multiple myeloma drug Pomalyst.

With $90 million in third-quarter sales, Pomalyst is kicking ass just three quarters into the launch.

Healthcare portfolio manager Ian Estepan picked up the significance in a tweet this morning:

Kyprolis is the multiple myeloma drug acquired by Amgen (AMGN - Get Report) in the $10 billion Onyx Pharmaceuticals deal. Both Kyprolis and Pomalyst are approved to treat patients with multiple myeloma that no longer responds to other drugs.

In other words, the two drugs compete for the same multiple myeloma patients, but so far, doctors seem to prefer Pomalyst over Kyprolis.

Kyprolis sales in the third quarter: $65 million, a touch weaker than Wall Street consensus.

The $90 million in Pomalyst sales for the third quarter trounced Wall Street expectations by $16 million, according to JP Morgan analyst Geoff Meacham.

Pomalyst is approved in the U.S. and Europe while Kyprolis is sold only stateside, but even Pomalyst U.S. sales of $77 million in the September quarter beat Kyprolis by a comfortable margin.

As Estepan points outs, Kyprolis received FDA approval in July 2012 while Pomalyst was approved this past February (European approval came in August.)

With less time on the market, Pomalyst is beating its closest competitor, which bodes well for Celgene as the company seeks to expand the drug's use into earlier stage multiple myeloma patients.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $154.25 0.00%
CELG $101.71 0.00%
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs